Funding Opportunity PAR-25-337 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes.

Notice NOT-CA-25-010 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-25-074 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites grant applications aimed at elucidating neuroimmune and neuronal-glial pathophysiological mechanisms of HIV-associated neurological disorders (HAND) using ex vivo culturing platforms derived from human induced pluripotent stem cells (hiPSC) in the presence of addictive substances. Specific emphasis is on unbiased, reproducible analysis of genetics and epigenetics, neuroglial interactions, and neuroimmune cell activities from the single cell to neural circuit levels.

Funding Opportunity PAR-25-056 from the NIH Guide for Grants and Contracts. The goal of this funding opportunity is to stimulate the use of existing human datasets for well-focused secondary analyses to investigate novel scientific ideas or new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the NHLBI mission.

Notice NOT-MH-25-055 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-362 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is tofurther elucidate the mechanisms of early immune development in utero, during the early post-natal period and during early childhood in neonates, infants, and children and adolescents with or without in-utero exposure to HIV or Anti-Retroviral Therapeutics (ART).This initiative aims to understand intricate mechanisms of immune cells at the maternal-fetal interface, T and B cell development and maturation in offspring, and local immune responses and the role of systemic immunity.

Funding Opportunity PAR-25-332 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications proposing research on current topics in Alzheimer's disease (AD) and its related dementias (ADRD). Further information on the high-priority topics of interest will be announced through a series of Notices published subsequent to this NOFO.

Funding Opportunity PAR-25-331 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications proposing new tests, animal models, techniques, etc. to advance research on Alzheimer's disease (AD) and its related dementias (ADRD) that need additional preliminary data with broader dissemination to establish them for more general use in this research field. The priority topics will be announced through a series of Notices published subsequent to this NOFO.

Notice NOT-EB-24-021 from the NIH Guide for Grants and Contracts

Notice NOT-AG-24-094 from the NIH Guide for Grants and Contracts

Notice NOT-DA-24-057 from the NIH Guide for Grants and Contracts

Notice NOT-HL-24-037 from the NIH Guide for Grants and Contracts

Notice NOT-CA-25-002 from the NIH Guide for Grants and Contracts

Notice NOT-AG-24-097 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-284 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Announcement (NOFO) is to encourage pilot research that is not an immediate precursor to testing a service intervention but is consistent with NIMH priorities for services research. While NIMH now requires use of an experimental therapeutics model for all intervention studies, there is recognition that some mission-relevant areas of services research do not involve clinical trials.

Funding Opportunity PAR-25-283 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Announcement (NOFO) is to encourage innovative research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial R01-level projects that address NIMH strategic priorities for mental health services research.

Funding Opportunity PAR-25-099 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to support the development of a comprehensive and well-defined product development strategy for next-generation treatments for HIV and HIV-associated comorbidities, coinfections and complication and preventive strategies for HIV, as well as facilitating the translation of research findings into drug products that enables submission of an Investigational New Drug (IND) application to the FDA.

Funding Opportunity PAR-25-374 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites applications that propose to use mouse models to conduct rigorous preclinical testing of drugs or drug combinations currently used for other conditions, as well as investigational drugs at various stages of clinical development, predicted to be efficacious in AD/ADRD. This initiative will also support preclinical testing of repurposable or investigational drug candidates in combination with non-pharmacologic interventions leading to robust translational outcomes. The central goal is to establish robust proof of concept that will enable rational drug repurposing and combination therapy development for the treatment and prevention of AD/ADRD.

Funding Opportunity RFA-EY-25-002 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to request applications that aim to implement and evaluate multi-level interventions and community engaged research in advancing vision equity. This Notice of Funding Opportunity (NOFO) supports research directed at preventing, reducing, or eliminating disparities in eye and vision health. Applications responding to this NOFO must involve multilevel interventions that simultaneously address vision health conditions and social determinants of health (SDOH) at one or more levels of influence, such as individual, interpersonal, organizational, and community. Research must include a focus on improving vision health in one or more NIH-designated Populations with Health Disparities. Additionally, research must demonstrate meaningful community engagement in the research process.

Funding Opportunity PAR-25-101 from the NIH Guide for Grants and Contracts. The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is underrepresented or not included in NIDA's current portfolio that has the potential to transform SUD research. The proposed research should: 1. develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research; and /or 2. test an innovative and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would transform current thinking.